Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension

Key Takeaways

• Phase 1 trial showed steady 24‑hour treprostinil plasma levels
• PK profile matched subcutaneous delivery with low peak‑to‑trough variation
• Dose proportionality across patch sizes enables simple titration
• Patch demonstrated acceptable safety and skin tolerability in volunteers
• Transdermal route could address adherence issues of existing prostacyclin therapies

Pulse Analysis

Pulmonary arterial hypertension remains a life‑threatening condition affecting roughly 45,000 Americans, with prostacyclin analogues such as treprostinil forming the cornerstone of therapy. Despite their efficacy, current delivery methods—continuous intravenous infusion, subcutaneous injection, or inhalation—pose significant burdens, including infection risk, infusion site pain, and complex dosing regimens that can erode patient adherence. The market for prostacyclin drugs exceeds $3 billion annually, underscoring both the clinical need and commercial opportunity for more patient‑friendly solutions.

Corsair Pharma’s TRX‑248 transdermal system seeks to replace invasive routes with a once‑daily skin patch that releases an inactive prodrug, which the liver converts to active treprostinil. In its first‑in‑human Phase 1 study, nine healthy volunteers achieved continuous plasma concentrations over 24 hours, mirroring the pharmacokinetics of subcutaneous administration while exhibiting low peak‑to‑trough fluctuation. The data also revealed dose proportionality across multiple patch sizes, simplifying titration, and demonstrated favorable safety with only mild skin irritation. These findings suggest the patch could deliver therapeutic exposure without the pain and inconvenience of injections.

The positive early data positions Corsair to pursue a 505(b)(2) regulatory pathway, potentially accelerating market entry and allowing the company to capture a share of the $2 billion treprostinil segment. If subsequent trials confirm efficacy and safety in PAH patients, the patch could improve quality of life, reduce healthcare utilization associated with infusion complications, and attract interest from insurers seeking cost‑effective chronic therapies. Investors will be watching the upcoming Phase 2/3 studies closely, as a successful transdermal prostacyclin could reshape the treatment landscape for pulmonary hypertension.